Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.33 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.32 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.31 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.31 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3299176 | 0.81 | TDP1 (0.41) | HPGDDDB1CRBNPOLBHTR2C | |
| SCHEMBL3302917 | 0.80 | HTR2C (0.38) | HPGDDDB1CRBNPOLBHTR2C | |
| SCHEMBL1563615 | 0.78 | S1PR1 (0.55) | S1PR1 | |
| SCHEMBL3301570 | 0.77 | HTR2C (0.36) | HPGDDDB1CRBNPOLBHTR2C | |
| SCHEMBL3304333 | 0.77 | S1PR1 (0.39) | HPGDDDB1CRBNPOLBHTR2C | |
| SCHEMBL1786072 | 0.75 | HTR2C (0.52) | HPGDDDB1CRBNPOLBHTR2C | |
| SCHEMBL1563166 | 0.74 | S1PR1 (0.45) | S1PR1 | |
| SCHEMBL4421908 | 0.72 | S1PR1 (0.43) | HTR2CHTR6S1PR1 | |
| SCHEMBL12677724 | 0.72 | S1PR1 (0.47) | HPGDPOLBHTR2CHTR6S1PR1 | |
| SCHEMBL2131088 | 0.71 | AR (0.47) | HPGDHTR2CHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2053038-B1 | AMINO ALCOHOL DERIVATIVE AND IMMUNOSUPPRESSIVE AGENT HAVING SAME AS AN ACTIVE INGREDIENT | KYORIN SEIYAKU KK (JP) | 2016-10-05 | — | — | EP | disclosed |
| EP-2058317-B1 | AMINOPHOSPHORIC ACID ESTER DERIVATIVE AND S1P RECEPTOR MODULATOR CONTAINING THE SAME AS ACTIVE INGREDIENT | KYORIN SEIYAKU KK (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-8476305-B2 | Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-8476305-B2 | Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-8476305-B2 | Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| CN-101506145-B | Aminoalcohol derivative and immunosuppressant containing the same as active ingredient | KYORIN SEIYAKU KK | 2013-05-29 | — | — | CN | disclosed |
| CN-101501049-B | Aminophosphoric acid ester derivative and S1P receptor modulator containing the same as active ingredient | KYORIN SEIYAKU KK | 2013-04-24 | — | — | CN | disclosed |
| US-8273748-B2 | Amino alcohol derivative and immunosuppresive agent having same as an active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273748-B2 | Amino alcohol derivative and immunosuppresive agent having same as an active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273748-B2 | Amino alcohol derivative and immunosuppresive agent having same as an active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20090325907-A1 | AMINO PHOSPHATE DERIVATIVE AND S1P RECEPTOR MODULATOR HAVING SAME AS AN ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090325907-A1 | AMINO PHOSPHATE DERIVATIVE AND S1P RECEPTOR MODULATOR HAVING SAME AS AN ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090325907-A1 | AMINO PHOSPHATE DERIVATIVE AND S1P RECEPTOR MODULATOR HAVING SAME AS AN ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| WO-2009099174-A1 | THERAPEUTIC AGENT OR PREVENTIVE AGENT FOR INFLAMMATORY BOWEL DISEASE CONTAINING AMINO ALCOHOL DERIVATIVE AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-08-13 | — | — | WO | disclosed |
| CN-101506145-A | Aminoalcohol derivative and immunosuppressant containing the same as active ingredient | KYORIN SEIYAKU KK (JP) | 2009-08-12 | — | — | CN | disclosed |
| CN-101501049-A | Aminophosphoric acid ester derivative and S1P receptor modulator containing the same as active ingredient | KYORIN SEIYAKU KK (JP) | 2009-08-05 | — | — | CN | disclosed |
| EP-2058317-A1 | AMINOPHOSPHORIC ACID ESTER DERIVATIVE AND S1P RECEPTOR MODULATOR CONTAINING THE SAME AS ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2009-05-13 | — | — | EP | disclosed |
| EP-2058317-A1 | AMINOPHOSPHORIC ACID ESTER DERIVATIVE AND S1P RECEPTOR MODULATOR CONTAINING THE SAME AS ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2009-05-13 | — | — | EP | disclosed |
| EP-2053038-A1 | AMINOALCOHOL DERIVATIVE AND IMMUNOSUPPRESSANT CONTAINING THE SAME AS AN ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2009-04-29 | — | — | EP | disclosed |
| EP-2053038-A1 | AMINOALCOHOL DERIVATIVE AND IMMUNOSUPPRESSANT CONTAINING THE SAME AS AN ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2009-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325907-A1 | AMINO PHOSPHATE DERIVATIVE AND S1P RECEPTOR MODULATOR HAVING SAME AS AN ACTIVE INGREDIENT | S1PR1, S1PR2, S1PR5 | HPGD 3317/4885DDB1 3787/4885CRBN 4171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.